A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* The patient must have relapsed ASPS that is in the opinion of the treating physician not resectable, or that resection would be associated with significant morbidity.
* The patient must provide informed consent.
* The only other eligibility criteria is adequate organ function, defined as creatinine clearance \>30 ml/min and LVEF \>45%.

Exclusion Criteria:

* Any active uncontrolled infection
* Any anti-cancer therapy within 21 calendar days prior to the first dose of lymphodepleting chemotherapy